TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01396239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-4658 (Eteplirsen)
Description: Treatment group 1 (n=4): 50.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 2 (n=4): 30.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 3 (n=4): matching placebo once weekly x 24 weeks via a 60-minute i.v. infusion; treatment group 3a will match two placebo subjects to 50.0 mg/kg eteplirsen; treatment group 3b will match two placebo subjects to 30.0 mg/kg eteplirsen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile, isotonic, clear, colorless phosphate buffered saline solution of eteplirsen at a concentration of 100 mg/mL in single-use vials containing a nominal volume of 1.0 mL without preservatives.
Study: NCT01114373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin
Description: Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.
Study: NCT00352976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m\^2 intravenous (IV)
Study: NCT03924011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Description: PBMT sessions will be planned 2x/week after RT.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: Sham laser sessions will be applied 2x/week after RT.
Study: NCT00352976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: total body irradiation (300 cGy) with thymic shielding will be given six days before the stem cells are given (day -6). Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: A target of 5 \* 10\^6/kg and a minimum of 4 \* 10\^6 CD34+ cell/kg recipient weight will be collected by apheresis and used for transplant. In most cases this dose will be recovered in a single apheresis; however, a second or rarely third apheresis performed on the following days may be required to achieve the minimum dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 \* 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).
Study: NCT04541667

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air
Description: Air will be used for luminal inflation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Dioxide
Description: Carbon dioxide will be used for luminal inflation.
Study: NCT03653182

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse, tongue image, and voice sound
Description: They are four diagnosis methods of TCM

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse, tongue image, and voice sound
Description: They are four diagnosis methods of TCM

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse, tongue image, and voice sound
Description: They are four diagnosis methods of TCM

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse, tongue image, and voice sound
Description: They are four diagnosis methods of TCM

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse, tongue image, and voice sound
Description: They are four diagnosis methods of TCM

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse, tongue image, and voice sound
Description: They are four diagnosis methods of TCM

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse, tongue image, and voice sound
Description: They are four diagnosis methods of TCM
Study: NCT00352976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
Study: NCT01093820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy-polyethyleneglycol epoetin beta
Description: Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
Study: NCT01833325

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation
Description: Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
Study: NCT00906867

Intervention type: OTHER
Intervention: Methacholine challenge testing
Description: Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
Study: NCT03653182

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse, tongue image, and voice sound
Description: They are four diagnosis methods of TCM
Study: NCT03369093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Twice daily doses of injectable amoxicillin
Study: NCT04944251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Exercise
Description: the third month, for 30 minutes or 1 hour, 3 days a week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Exercise
Description: the third month, for 30 minutes or 1 hour, 3 days a week
Study: NCT00906867

Intervention type: PROCEDURE
Intervention: Rhino-laryngoscopy
Description: Topical anesthesia (Xylocain Pump spray) followed by transnasal fiberoptic laryngoscopy with a flexible fiberoptic laryngoscope.
Study: NCT02450734

Intervention type: PROCEDURE
Intervention: Ultrasound-guided intermediate cervical plexus block
Study: NCT03297281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance of OAC in surgery of BPH by PVP.
Description: The maintenance of AVK or DOACs treatment in the perioperative setting (without interruption of oral treatment).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discontinuation of OAC in surgery of BPH by PVP.
Description: The discontinuation of AVK or DOACs treatment with perioperative heparin relay during postoperative course.
Study: NCT03215082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular-Visual Intervention
Description: vestibular-visual exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard care
Study: NCT01985542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: birch pollen subcutaneous immunotherapy
Description: birch pollen subcutaneous immunotherapy
Study: NCT02572531

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri DSM 17938/ATCC PTA
Description: Ingestion of active lozenge three times daily for 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of placebo lozenge three times daily for 2 weeks
Study: NCT03364166

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical excision
Description: * Under general anaesthesia, the buccal squamous cell carcinoma which invaded the buccinator muscle will be excised with the skin of the cheek. This will be done by a safety margins in the soft tissue and the mandible may be resected according to the plan and the invasion of the tumour.~* A neck dissection will be done in all cases of negative or positive neck lymph node.~* Reconstruction of the soft tissue will be done immediately by a major pectorals flap with the skin, also bony reconstruction may be done by a reconstructed plate at the time of surgery then the patients will be prepared for bone graft in another surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical excision
Description: * Under general anaesthesia, the buccal squamous cell carcinoma which invaded the buccinator muscle will be excised with the skin of the cheek. This will be done by a safety margins in the soft tissue and the mandible may be resected according to the plan and the invasion of the tumour.~* A neck dissection will be done in all cases of negative or positive neck lymph node.~* Reconstruction of the soft tissue will be done immediately by a major pectorals flap with the skin, also bony reconstruction may be done by a reconstructed plate at the time of surgery then the patients will be prepared for bone graft in another surgery.
Study: NCT03982563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Mindset
Description: Reading and writing activities designed to instill the belief that people can change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude
Description: Reading and writing activities designed to practice noticing and appreciating good things in life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Reading and writing activities designed to identify and schedule positive activities.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Study Skills
Description: Reading and writing activities designed to learn evidence-based study strategies.
Study: NCT00324311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGD
Description: Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DGD
Description: Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
Study: NCT03546803

Intervention type: OTHER
Intervention: 3M™ Cavilon™ Advanced Skin Protectant
Description: liquid skin protectant on skin to protect from radiation dermatitis

Intervention type: OTHER
Intervention: 3M™ Cavilon™ Advanced Skin Protectant
Description: liquid skin protectant on skin to protect from radiation dermatitis

Intervention type: OTHER
Intervention: 3M™ Cavilon™ Advanced Skin Protectant
Description: liquid skin protectant on skin to protect from radiation dermatitis
Study: NCT00851643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octavalent HPV with 15 mcg IMX / AAHS
Description: 0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octavalent HPV with 30 mcg IMX / AAHS
Description: 0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octavalent HPV with 60 mcg IMX / AAHS
Description: 0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octavalent HPV with 120 mcg IMX / AAHS
Description: 0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)
Description: 0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)
Description: 0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
Study: NCT03106558

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty using Manual Instrumentation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty using Robotic Arm
Study: NCT01856036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
Study: NCT03403166

Intervention type: BEHAVIORAL
Intervention: DASH diet
Description: Diet intervention

Intervention type: BEHAVIORAL
Intervention: Fruits and vegetables diet
Description: Diet intervention

Intervention type: BEHAVIORAL
Intervention: Control diet
Description: Diet intervention
Study: NCT02612220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BioFoam® Surgical Matrix
Description: Complete hemostasis is achieved by direct application of BioFoam® (Cryolife Inc., Kennesaw, GA) to the transection surface area of the liver. In addition, the surgeon may use conventional methods such as argon beam coagulation and warm sponges. If more than one syringe of BioFoam® is required to cover the entire transection surface area, a second syringe maybe used. BioFoam® Surgical Matrix will be used according to the supplier's instructions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative hemostasis
Description: Complete hemostasis will be achieved without the use of topical agents
Study: NCT01222390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour Profile Tissue Expander
Description: The Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. This increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. Additionally, the suture tabs on the back of the expander hold the expander in place and prevent malposition and displacement.
Study: NCT01009671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART 44

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART 50
Study: NCT02479373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ren-Ex Machine
Description: The exercise is performed once per week with individualized instruction using moderate resistance on Ren-Ex Machines, ultra-low-friction equipment to minimize force on joints.

Intervention type: OTHER
Group type: OTHER
Intervention: Dual-Emission X-ray Absorptiometry (DEXA) scan
Description: To study body composition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-Emission X-ray Absorptiometry (DEXA) scan
Description: To study body composition

Intervention type: OTHER
Group type: OTHER
Intervention: Biodex dynamometer
Description: To study muscle strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodex dynamometer
Description: To study muscle strength

Intervention type: OTHER
Group type: OTHER
Intervention: Sub-maximal test
Description: To study lung capacity, a sub-maximal (limited exercise) test on a stationary bicycle is performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-maximal test
Description: To study lung capacity, a sub-maximal (limited exercise) test on a stationary bicycle is performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires
Study: NCT02951637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus carboplatin combined with gefitinib
Description: Pemetrexed (500mg/m(2) d1) plus carboplatin (AUC5 d1) combined with gefitinib (250mg d4-28) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with gefitinib every four weeks.
Study: NCT00750308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo matching ramipril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo matching ramipril
Study: NCT02951637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib (250mg daily)
Study: NCT00655837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40
Description: 4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
Study: NCT00020566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Given IV
Study: NCT00750308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo matching ramipril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo matching tadalafil
Study: NCT03531736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (Rabbit)
Description: ATG (2 mg/kg/d IV on days-8 through -7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: fludarabine (30 mg/m2/d on days -5 through -2)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: TBI 200 cGy (days -2 and -1) given post stem cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: Rituxan (200 mg/m2) will be given to reduce the risk of EBV viremia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Allogeneic Hematopoietic Stem Cell Transplantation
Study: NCT04043286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Definitive abutment
Description: With two height options available, On1 Base are selected depending on the thickness of the soft tissue. It remains in position from implant placement to finalization, which leaves the soft tissue undisturbed for optimized healing, moved the restorative platform of Nobel Biocare conical connection implants from bone level to tissue level, thereby simplifying the restorative procedures
Study: NCT03893526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto
Description: Single dose administration of entresto
Study: NCT00020566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given orally and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT03893526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto
Description: Single dose administration of entresto

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Single dose administration of sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Single dose administration of sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: single doses administration of valsartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo day
Study: NCT03430349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel OPV2 candidate 1
Description: Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~* Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel OPV2 candidate 2
Description: Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission.
Study: NCT02122380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg by mouth daily for 30 Days
Study: NCT00372762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
Study: NCT02122380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg by mouth daily for 30 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 placebo pill by mouth per day for 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 placebo pill by mouth per day for 30 days
Study: NCT05152511

Intervention type: COMBINATION_PRODUCT
Intervention: Hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy is a specially designed cabinet for infants and neonates with a barometric pressure equal to 760 mmHg for 20 minutes daily, then gradually increase up to one hour daily for 5 days per week (fig. 1). The chamber was kept warm. The babies were fed before entering the chamber and if signs of hunger appear during therapy. The baby was continuously monitored with pulse oximeter. Older children are managed in the conventional Hyperbaric oxygen chamber with the same regimen.
Study: NCT02964377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (+)- Epicatechin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (+)- Epicatechin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (+)- Epicatechin